PRESS RELEASES

Stay up to date on the progress of OxThera and the development of Oxabact®.

All press releases

OxThera presents full 24-month data for Oxabact ® in Primary Hyperoxaluria type 1 (PH1) patients with ESRD at Kidney Week 2019

WASHINGTON D.C., US – November 7, 2019. OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today presents data from a 24-month interim analysis of an ongoing phase 2 trial evaluating Oxabact® in PH type 1 (PH1) patients with end stage renal disease (ESRD). The results showing…

Read More

OxThera receives positive decision from EMA on Paediatric Investigational Plan (PIP) for treatment of primary hyperoxaluria with Oxalobacter formigenes

STOCKHOLM, SWEDEN – August 23, 2019. OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today announced that, based on a positive opinion from the Paediatric Committee (PDCO), the EMA has agreed to the proposed PIP for Oxalobacter formigenes in the treatment of primary hyperoxaluria.

Read More

OxThera presents continuous strong data from an interim analysis of its Phase 2 study with Oxabact in Primary Hyperoxaluria

STOCKHOLM, SWEDEN – June 27, 2019. OxThera AB, a privately-held biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria (PH), today announced continuous strong data from a two-year interim analysis of its Phase 2 study with Oxabact® in PH.

Read More

OxThera initiates extension part of a Phase 3 study of Oxabact in Primary Hyperoxaluria

STOCKHOLM, SWEDEN – June 20, 2019. OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label extension part. All clinics participating in the study will continue to…

Read More

OxThera AB is being granted US patent for Oxalobactersecretagogues

OxThera AB, a privately-held Stockholm-based biopharmaceutical company, today announced a granted US patent on Oxalobacter formigenes secretagogues. Oxabact® , a formulation of highly concentrated lyophilized Oxalobacter formigenes, is being developed by OxThera AB as a potential treatment for patients with primary hyperoxaluria (PH). Oxabact® is designed to increase the intestinal secretion of oxalate from  plasma and thereby decrease and…

Read More

OxThera presents encouraging 52-week efficacy and safety data for Oxabact® in Primary Hyperoxaluria type 1 (PH1) patients with ESRD

OxThera AB, a Stockholm-based privately-held biopharmaceutical company and leader in the field of microbiome derived biotherapeutics, today announced a poster presentation showing encouraging Oxabact® efficacy and safety data from the longterm study OC5-OL-01, at the Annual Meeting of the American Society of Nephrology Kidney Week 2018 in San Diego. ”We are pleased to present the initial…

Read More

Hugo Petit Appointed CFO of OxThera

Stockholm – 7  September 2018 – OxThera AB, a Stockholm-based privately-held rare disease company today announced the appointment of Hugo Petit as its new Chief Financial Officer. Mr Petit previously served as the Chief Financial Officer of MedCap AB. While at MedCap, Hugo led the company’s listing on Nasdaq Stockholm. Prior to joining MedCap, Hugo held…

Read More

OxThera updates on Phase 3 study with Oxabact® in Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that the Phase 3 study with Oxabact® in Primary Hyperoxaluria (PH) is now fully open for recruitment.  All clinics participating in the study are approved by Competent authorities in Europe and US and are initiating patient screening. ”We are pleased to announce that we are now fully…

Read More

OxThera announces the appointment of Dr Alain Munoz to its Board of Directors

Stockholm – 13 June 2018 – OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the appointment of Dr Alain Munoz to its board of directors. “It is my pleasure to welcome Alain to the board of Oxthera”, said Dr. Georges Gemayel, Chairman…

Read More

OxThera announces the randomization of the first patient into its phase III EPHEX study with Oxabact

Stockholm – 15 March 2018 – OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact. Study OC5-DB-02 (EPHEX) is a randomized, placebo-controlled, 52-week study with the goal to investigate…

Read More

OxThera Strengthens Patent Portfolio for treatment of Hyperoxaluria

OxThera AB announced today that it has recently been granted two new US patents, three new European patents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The newly granted US patents have numbers US8900575 and…

Read More

OxThera appoints new Chief Medical Officer

Stockholm – 12 October 2017 – OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Dr Bastian Dehmel as their new Chief Medical Officer. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a severe and often fatal disease in children, and where there are currently no available therapies. The…

Read More

Matthew Gantz Appointed CEO of Oxthera

Stockholm – 5 July 2017 – OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Matthew Gantz as their new CEO. He succeeds Elisabeth Lindner as CEO, who will continue as COO of Oxthera overseeing the Oxabact program. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal disease…

Read More

OxThera Raises EUR 32 Million to Complete Development of Oxabact® for Treatment of Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, announces today that it has agreed on a EURO 32 million investment to complete the Oxabact®development program for treatment of Primary hyperoxaluria.    The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest, Sweden, in addition to current shareholders…

Read More

Archive

2019

OxThera presents full 24-month data for Oxabact ® in Primary Hyperoxaluria type 1 (PH1) patients with ESRD at Kidney Week 2019

WASHINGTON D.C., US – November 7, 2019. OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today presents data from a 24-month interim analysis of an ongoing phase 2 trial evaluating Oxabact® in PH type 1 (PH1) patients with end stage renal disease (ESRD). The results showing…

Read More

OxThera receives positive decision from EMA on Paediatric Investigational Plan (PIP) for treatment of primary hyperoxaluria with Oxalobacter formigenes

STOCKHOLM, SWEDEN – August 23, 2019. OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today announced that, based on a positive opinion from the Paediatric Committee (PDCO), the EMA has agreed to the proposed PIP for Oxalobacter formigenes in the treatment of primary hyperoxaluria.

Read More

OxThera presents continuous strong data from an interim analysis of its Phase 2 study with Oxabact in Primary Hyperoxaluria

STOCKHOLM, SWEDEN – June 27, 2019. OxThera AB, a privately-held biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria (PH), today announced continuous strong data from a two-year interim analysis of its Phase 2 study with Oxabact® in PH.

Read More

OxThera initiates extension part of a Phase 3 study of Oxabact in Primary Hyperoxaluria

STOCKHOLM, SWEDEN – June 20, 2019. OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label extension part. All clinics participating in the study will continue to…

Read More

2018

OxThera AB is being granted US patent for Oxalobactersecretagogues

OxThera AB, a privately-held Stockholm-based biopharmaceutical company, today announced a granted US patent on Oxalobacter formigenes secretagogues. Oxabact® , a formulation of highly concentrated lyophilized Oxalobacter formigenes, is being developed by OxThera AB as a potential treatment for patients with primary hyperoxaluria (PH). Oxabact® is designed to increase the intestinal secretion of oxalate from  plasma and thereby decrease and…

Read More

OxThera presents encouraging 52-week efficacy and safety data for Oxabact® in Primary Hyperoxaluria type 1 (PH1) patients with ESRD

OxThera AB, a Stockholm-based privately-held biopharmaceutical company and leader in the field of microbiome derived biotherapeutics, today announced a poster presentation showing encouraging Oxabact® efficacy and safety data from the longterm study OC5-OL-01, at the Annual Meeting of the American Society of Nephrology Kidney Week 2018 in San Diego. ”We are pleased to present the initial…

Read More

Hugo Petit Appointed CFO of OxThera

Stockholm – 7  September 2018 – OxThera AB, a Stockholm-based privately-held rare disease company today announced the appointment of Hugo Petit as its new Chief Financial Officer. Mr Petit previously served as the Chief Financial Officer of MedCap AB. While at MedCap, Hugo led the company’s listing on Nasdaq Stockholm. Prior to joining MedCap, Hugo held…

Read More

OxThera updates on Phase 3 study with Oxabact® in Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that the Phase 3 study with Oxabact® in Primary Hyperoxaluria (PH) is now fully open for recruitment.  All clinics participating in the study are approved by Competent authorities in Europe and US and are initiating patient screening. ”We are pleased to announce that we are now fully…

Read More

OxThera announces the appointment of Dr Alain Munoz to its Board of Directors

Stockholm – 13 June 2018 – OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the appointment of Dr Alain Munoz to its board of directors. “It is my pleasure to welcome Alain to the board of Oxthera”, said Dr. Georges Gemayel, Chairman…

Read More

OxThera announces the randomization of the first patient into its phase III EPHEX study with Oxabact

Stockholm – 15 March 2018 – OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact. Study OC5-DB-02 (EPHEX) is a randomized, placebo-controlled, 52-week study with the goal to investigate…

Read More

2017

OxThera Strengthens Patent Portfolio for treatment of Hyperoxaluria

OxThera AB announced today that it has recently been granted two new US patents, three new European patents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The newly granted US patents have numbers US8900575 and…

Read More

OxThera appoints new Chief Medical Officer

Stockholm – 12 October 2017 – OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Dr Bastian Dehmel as their new Chief Medical Officer. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a severe and often fatal disease in children, and where there are currently no available therapies. The…

Read More

Matthew Gantz Appointed CEO of Oxthera

Stockholm – 5 July 2017 – OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Matthew Gantz as their new CEO. He succeeds Elisabeth Lindner as CEO, who will continue as COO of Oxthera overseeing the Oxabact program. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal disease…

Read More

2016

OxThera Raises EUR 32 Million to Complete Development of Oxabact® for Treatment of Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, announces today that it has agreed on a EURO 32 million investment to complete the Oxabact®development program for treatment of Primary hyperoxaluria.    The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest, Sweden, in addition to current shareholders…

Read More